CTI BioPharma Corp (NASDAQ:CTIC) has received a consensus rating of “Buy” from the eight research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $6.40.
A number of brokerages have recently commented on CTIC. ValuEngine raised CTI BioPharma from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. BidaskClub cut CTI BioPharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 14th. Zacks Investment Research lowered CTI BioPharma from a “hold” rating to a “sell” rating in a research note on Thursday, July 12th. Finally, JMP Securities set a $8.00 price objective on CTI BioPharma and gave the company a “buy” rating in a research note on Tuesday, July 10th.
Several large investors have recently added to or reduced their stakes in CTIC. NEA Management Company LLC bought a new stake in shares of CTI BioPharma during the 1st quarter valued at $14,625,000. Franklin Resources Inc. bought a new stake in shares of CTI BioPharma during the 1st quarter valued at $13,542,000. BlackRock Inc. raised its stake in shares of CTI BioPharma by 546.2% during the 2nd quarter. BlackRock Inc. now owns 2,803,182 shares of the biopharmaceutical company’s stock valued at $13,958,000 after purchasing an additional 2,369,398 shares during the period. Millennium Management LLC bought a new stake in shares of CTI BioPharma during the 1st quarter valued at $3,068,000. Finally, Algert Global LLC bought a new stake in shares of CTI BioPharma during the 2nd quarter valued at $1,086,000. Institutional investors own 62.76% of the company’s stock.
CTI BioPharma (NASDAQ:CTIC) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. CTI BioPharma had a negative return on equity of 90.92% and a negative net margin of 313.77%. The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.30 million. equities analysts expect that CTI BioPharma will post -0.6 EPS for the current fiscal year.
CTI BioPharma Company Profile
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Further Reading: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.